MAHMOUDREZA POURKARIM

Dr. MAHMOUDREZA POURKARIM

KU Leuven, Department of Microbiology, Immunology and Transplantation, Rega Institute, Laboratory for Clinical and Epidemiological Virology, Herestraat 49, Post box 1040, BE-3000 Leuven, Belgium
orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2014 in World Journal of Gastroenterology
Verified
Journal Article
Open access
MAHMOUDREZA POURKARIMMAHMOUDREZA POURKARIM
MAHMOUDREZA POURKARIM
SASamad Amini-Bavil-Olyaee
Samad Amini-Bavil-Olyaee
FKFuat Kurbanov
Fuat Kurbanov
MRMarc Van Ranst
Marc Van Ranst
Frank TackeFrank Tacke
Frank Tacke
The clinical course of infections with the hepatitis B virus (HBV) substantially varies between individuals, as a consequence of a complex interplay between viral, host, environmental and other factors. Due to the high genetic variability of HBV, the virus can be categorized into different HBV genotypes and subgenotypes, which considerably differ with respect to geographical distribution, transmission routes, disease progression, responses to antiviral therapy or vaccination, and clinical outcome measures such as cirrhosis or hepatocellular carcinoma. However, HBV (sub)genotyping has caused some controversies in the past due to misclassifications and incorrect interpretations of different genotyping methods. Thus, an accurate, holistic and dynamic classification system is essential. In this review article, we aimed at highlighting potential pitfalls in genetic and phylogenetic analyses of HBV and suggest novel terms for HBV classification. Analyzing full-length genome sequences when classifying genotypes and subgenotypes is the foremost prerequisite of this classification system. Careful attention must be paid to all aspects of phylogenetic analysis, such as bootstrapping values and meeting the necessary thresholds for (sub)genotyping. Quasi-subgenotype refers to subgenotypes that were incorrectly suggested to be novel. As many of these strains were misclassified due to genetic differences resulting from recombination, we propose the term "recombino-subgenotype". Moreover, immigration is an important confounding facet of global HBV distribution and substantially changes the geographic pattern of HBV (sub)genotypes. We therefore suggest the term "immigro-subgenotype" to distinguish exotic (sub)genotypes from native ones. We are strongly convinced that applying these two proposed terms in HBV classification will help harmonize this rapidly progressing field and allow for improved prophylaxis, diagnosis and treatment.

1 April 2010 in Journal of Clinical Virology
Verified
Journal Article
Closed access
MAHMOUDREZA POURKARIMMAHMOUDREZA POURKARIM
MAHMOUDREZA POURKARIM
SASamad Amini-Bavil-Olyaee
Samad Amini-Bavil-Olyaee
PLPhilippe Lemey
Philippe Lemey
PMPiet Maes
Piet Maes
MRMarc Van Ranst
Marc Van Ranst

2 May 2021 in Archives of Virology
Verified
Journal Article
Closed access
PDF file
SHSeyed Mohammad Ali Hashemi
Seyed Mohammad Ali Hashemi
MTMarijn Thijssen
Marijn Thijssen
SHSeyed Younes Hosseini
Seyed Younes Hosseini
ATAlijan Tabarraei
Alijan Tabarraei
MAHMOUDREZA POURKARIMMAHMOUDREZA POURKARIM
MAHMOUDREZA POURKARIM
JSJamal Sarvari
Jamal Sarvari

29 April 2008 in Gut
Verified
Journal Article
Closed access
PDF file
JVJ Verbeeck
J Verbeeck
GAG Van Assche
G Van Assche
JRJ Ryding
J Ryding
EWE Wollants
E Wollants
KRK Rans
K Rans
PRP Rutgeerts
P Rutgeerts
Background and aims: Anti-α4 integrin therapy with natalizumab is efficacious in refractory Crohn’s disease and in multiple sclerosis, but carries an estimated 1/1000 risk of progressive multifocal leukoencephalopathy (PML) caused by reactivation of latent JC virus infection. Athough anti-α4 integrin therapies are likely to be introduced in the clinic, screening for the risk of PML has not been developed. Methods: We prospectively collected urine, serum, plasma and buffy coats from 125 patients with Crohn’s disease, 100 control subjects with gastrointestinal (GI) disease, and 106 healthy volunteers. Four to eight weeks after this first sample collection, we additionally collected a set of urine, serum, plasma and buffy coat samples from the 125 patients with Crohn’s disease, and a next set of samples was collected 12–16 weeks after the first collection. JC viral loads were determined with quantitative real-time polymerase chain reaction (PCR), and JC virus seroprevalence with a specific enzyme-linked immunosorbant assay (ELISA). Results: The overall JC virus seroprevalence was 65%. JC virus DNA copies were detected in the urine from 29–44% of subjects, both those with Crohn’s disease and controls. Median viral loads were significantly higher in patients with Crohn’s disease who were immunosuppressed (7.36×106 copies/ml) compared to healthy volunteers (2.77×105 copies/ml) and compared to GI controls (1.8×106 copies/ml). Clearance at any time point occurred in 4/107 (3.7%) subjects only. JC viraemia was found in two patients with Crohn’s disease. Conclusions: The natural history of JC virus in patients with Crohn’s disease is still unknown. Our study results show that JC virus latency and urine viral shedding is frequent in immunosuppressed patients with Crohn’s disease. More prospective studies are needed in order to agree on possible recommendations concerning the exclusion of patients with JCV viraemia from anti-α4 integrin treatment.

1 January 2010 in Journal of Clinical Virology
Verified
Journal Article
Closed access
MAHMOUDREZA POURKARIMMAHMOUDREZA POURKARIM
MAHMOUDREZA POURKARIM
PLPhilippe Lemey
Philippe Lemey
SASamad Amini-Bavil-Olyaee
Samad Amini-Bavil-Olyaee
PMPiet Maes
Piet Maes
MRMarc Van Ranst
Marc Van Ranst

1 October 2020 in EBioMedicine
Verified
Journal Article
Open access
MTMarijn Thijssen
Marijn Thijssen
FTFrank Tacke
Frank Tacke
LBLeen Beller
Leen Beller
WDWard Deboutte
Ward Deboutte
KYKwe Claude Yinda
Kwe Claude Yinda
MAHMOUDREZA POURKARIMMAHMOUDREZA POURKARIM
MAHMOUDREZA POURKARIM
The role of the microbiome in liver transplantation (LT) outcome has received a growing interest in the past decades. In contrast to bacteria, the role of endogenous viral communities, known as the virome, is poorly described. Here, we applied a viral metagenomic approach to study the dynamic evolution of circulating viruses in the plasma of LT recipients and its effect on the clinical course of patients. Patients chronically infected with hepatitis B virus (HBV) that received a LT due to endstage liver disease were included in this study. Longitudinal plasma samples were collected pre- and post-LT. Intact viral particles were isolated and sequenced on an Illumina HiSeq 2500 platform. Short read libraries were analysed with an in-house bioinformatics pipeline. Key endpoints were the dynamics of viral families and post-LT complications. The initiation of immunosuppression induced a bloom of the Anelloviridae that dominated the post-LT plasma virome. A variety of post-LT complication were observed. Nephrotoxicity was reported in 38% of the patients and was associated with a high abundance of anelloviruses. Besides nephrotoxicity, 16 (67%) patients experienced flares of viral or bacterial infections in post-transplant follow-up. These flares were recognized by an increased burden of anelloviruses (p < 0.05). Interestingly, no mortality was observed in patients infected with human pegivirus. These findings suggest a diagnostic potential for the Anelloviridae family in post-LT complications. Furthermore, the impact of human pegivirus infection on post-transplant survival should be further investigated. This trial was supported by Gilead Sciences grant number BE-2017-000133.